VINCASAR PFS Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Vincasar Pfs, and when can generic versions of Vincasar Pfs launch?
Vincasar Pfs is a drug marketed by Teva Parenteral and is included in one NDA.
The generic ingredient in VINCASAR PFS is vincristine sulfate. There are thirteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the vincristine sulfate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VINCASAR PFS?
- What are the global sales for VINCASAR PFS?
- What is Average Wholesale Price for VINCASAR PFS?
Summary for VINCASAR PFS
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 42 |
| Clinical Trials: | 93 |
| Patent Applications: | 4,626 |
| DailyMed Link: | VINCASAR PFS at DailyMed |
Recent Clinical Trials for VINCASAR PFS
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Medical College of Wisconsin | Phase 1 |
| Yazeed Sawalha | Phase 1 |
| Memorial Sloan Kettering Cancer Center | Early Phase 1 |
US Patents and Regulatory Information for VINCASAR PFS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Parenteral | VINCASAR PFS | vincristine sulfate | INJECTABLE;INJECTION | 071426-001 | Jul 17, 1987 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
